Affiliation:
1. Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, 272 01 Kladno, Czech Republic
2. Department of Public Health, Faculty of Health and Social Work, Trnava University, 917 01 Trnava, Slovakia
Abstract
Slovakia has adopted an amendment to Act No. 363/2011, regulating, among other things, drug reimbursement and is undergoing a significant change in the availability of innovative treatments for patients. High expectations are associated with arrangements related to performance-based managed entry agreements. Opinions and positions towards this change appear to be inconsistent, and for the further application of the law in practice and when setting up the main implementation processes, it is necessary to understand the positions and opinions of the individual actors who are involved in the PB-MEA process. The interviews were conducted in the period from 20 May to 15 August 2022 around the same time as the finalisation of the amendment to Act No. 363/2011 and its adoption. A roughly one-hour open interview was conducted on a sample of 12 stakeholders in the following groups: representatives of the Ministry of Health, health-care providers, pharmaceutical companies and others, including a health insurance company. The main objective was to qualitatively describe the perception of this topic by key stakeholders in Slovakia. The responses were analysed using MAXQDATA 2022 software to obtain codes associated with key expressions. We identified three main strong top categories of expressions that strongly dominated the pro-management interviews with stakeholders: legislation, opportunities and threats. Ambiguity and insufficient coverage of the new law, improved availability of medicinal products and threats associated with data, IT systems and potentially unfavourable new reimbursement schemes were identified as key topics of each of the said top categories, respectively. Among individual sets of respondents, there is frequent consensus on both opportunities and threats in the area of implementing process changes in PB-MEA. For the successful implementation of the law in practice, some basic threats need to be removed, among which in particular is insufficient data infrastructure.
Funder
Czech Technical University in Prague
Subject
Health Information Management,Health Informatics,Health Policy,Leadership and Management
Reference25 articles.
1. Wenzl, M., and Chapman, A.S. (2019). Performance-Based Managed Entry Agreements for New Medicines in OECD Countries and EU Member States: How They Work and Possible Improvements Going forward, OECD. OECD Health Working Papers.
2. Drug Policy in Slovakia;Psenkova;Value Health Reg. Issues,2017
3. Lehocká, A., Kocková, S., and Matúš, M. (EY, 2022). Novela zákona č. 363/2011—Navrhované zmeny a ich dopad na opravu DPH v súvislosti so spätnými platbami voči zdravotným poisťovniam, EY.
4. What principles should govern the use of managed entry agreements?;Klemp;Int. J. Technol. Assess. Health Care,2011
5. Risk sharing in managed entry agreements—A review of the Swedish experience;Andersson;Health Policy,2020
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献